tbuckley/cabot-search huggingface dataset:
When Radiotherapy and Immunotherapy Dance—Who Leads So as Not to Step on Toes?
Authors: Fiyinfolu Balogun, David Raben
Journal: JAMA Oncology (2022)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
BOOK REVIEWS
Authors: C. A. STEIN
Journal: JNCI Journal of the National Cancer Institute (1988)

BOOK REVIEWS The Basic Science of Oncology. I. Tannock. R. Hill, eds. New York: Pergamon Press, 1987, 398 pp. $37.50. C. A. STEIN C. A. STEIN Clinical Pharmacology Branch, Division of Cancer Treatment National Cancer InstituteBethesda, MD 20892 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 80, Issue 4, 20 April 1988, Page 287, https://doi.org/10.1093/jnci/80.4.287 Published: 20 April 1988
TCT-237 Long-Term Clinical Outcomes of Multiple Overlapping (≥60mm) Everolimus-Eluting Stent Implantation
Authors: Pil Hyung Lee, Sang Soo Cheon, Min Su Kim, Hee-Soon Park, Jae Hyung Roh, Jung-Min Ahn, Young-Hak Kim, Duk-Woo Park, Sung-Han Yoon, Hyun Woo Park, Mineok Chang, Jong-Young Lee, Soo-Jin Kang, Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2014)
Rigidity of Cell Fate and Function Among Monocytes
Authors: Catherine Rhee, Elizabeth W Scadden, Lai Ping Wong, Giulia Schiroli, Michael Mazzola, Phillip Chea, Hiroki Kato, Friedrich F Hoyer, Meeta Mistry, Bum-Kyu Lee, Jonghwan Kim, Matthias Nahrendorf, Michael K Mansour, David Sykes, Ruslan I Sadreyev, David T. Scadden
Journal: Blood (2021)
Medicolegal
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Academic Degree and Missing Citations
Authors: Karla Kerlikowske, Kathryn Phillips, Steve Cummings, Peter Salzmann, Jane Cauley
Journal: JAMA (2000)

In Reply: To make evidenced-based recommendations related to breast cancer screening of elderly women, the efficacy (or lack thereof) of screening mammography needs to be better defined.Additional time preference and utility data are also needed, and guidelines for a threshold for average life expectancy gained and cost per year of life saved are required.In the meantime, elderly women and their physicians must decide whether to continue or discontinue screening mammography at age 70 years.In an effort to build a clinically relevant and useful model to facilitate this decision, we focused on the 2 most important factors that would influence decisions about screening in the elderly: (1) level of breast cancer risk determined by age and BMD measurement, and (2) time preference or discount rate.Even without precisely defining an individual woman's physiologic age, breast cancer risk, discount rate and utilities, a clinician can make a reasonable recommendation based on our model.Elderly women with normal or high BMD and a strong preference for preventive care may choose to undergo mammography while women with existing comorbid conditions and low BMD whose chance of dying of breast cancer is very low may choose not to undergo mammography since the chance of benefiting from screening is very small.Given the small average gains in life expectancy (2.1 days) from screening elderly women with normal to high BMD, even those at relatively high risk and without comorbid conditions, the chance that average life expectancy would be increased to more than 30 days (a gain from a preventive intervention considered to be large 1 ) is small.Although the number of cases is small, Dr Rozenberg and colleagues report some interesting data that support the association between breast cancer and high BMD.Other studies have found that high estrogen levels are associated with breast cancer, 2 suggesting a central role for estrogen in both diseases.Technically, Drs Seidenwurm and Breslau are correct that time costs are part of the total cost of an intervention.However, it is often assumed that quality adjusted life years incorporate these time costs.Therefore, it would be redundant to include them as a separate cost. 3 It is important to recognize that older women differ significantly in their risk for breast cancer and their preferences for a small gain in life expectancy and the potential harms of screening mammography.The emphasis should be to identify groups of elderly women willing to undergo mammography (with its attendant harms-time, money, discomfort, additional tests and surgeries) and who are also most likely to benefit from screening.Conversely, it is important to identify elderly women who are unlikely to benefit from screening so they will not be subjected to the potential harms of mammography. 4Our goal is to help physicians identify those elderly women who may benefit the most from screening mammography and to help elderly women make an informed decision about continuing screening mammography.
Germline Genetic Variation in ETV6 and Predisposition to Childhood Acute Lymphoblastic Leukemia
Authors: Takaya Moriyama, Monika Metzger, Gang Wu, Rina Nishii, Maoxiang Qian, Meenakshi Devidas, Wenjian Yang, Emily Quinn, Julie Gastier-Foster, Elizabeth Raetz, Eric C. Larsen, Paul L. Martin, W. Paul Bowman, Naomi J. Winick, Yoshihiro Komada, Elaine R Mardis, Robert Fulton, Ching-Hon Pui, William E. Evans, Jinghui Zhang, Stephen P Hunger, Mary V. Relling, Kim E Nichols, Mignon Loh, Jun J Yang
Journal: Blood (2015)
Effect of a Community-Based Medical Oncology Depression Screening Program on Behavioral Health Referrals Among Patients With Breast Cancer
Authors: Erin E. Hahn, Corrine E. Munoz-Plaza, Dana Pounds, Lindsay Joe Lyons, Janet S. Lee, Ernest Shen, Benjamin D. Hong, Shannon La Cava, Farah M. Brasfield, Lara N. Durna, Karen W. Kwan, David B. Beard, Alexander Ferreira, Aswini Padmanabhan, Michael K. Gould
Journal: JAMA (2022)

Implementation of guideline-recommended depression screening in medical oncology remains challenging. Evidence suggests that multicomponent care pathways with algorithm-based referral and management are effective, yet implementation of sustainable programs remains limited and implementation-science guided approaches are understudied.
Uric Acid as a Factor in the Causation of Disease.—A Contribution to the Pathology of High Blood Pressure, Headache, Epilepsy, Mental Depression, Paroxysmal Hemoglobinuria and Anemia, Bright's Disease, Gout, Rheumatism and other Disorders.
Journal: JAMA (1898)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lesion-level response to immune checkpoint inhibitor in patients with advanced gastric cancer.
Authors: Iori Motoo, Takayuki Ando, Shinya Kajiura, Kohei Ogawa, Kenichiro Tsukada, Akira Ueda, Nobuhiro Suzuki, Naokatsu Nakada, Koji Nakashima, Ayumu Hosokawa, Ichiro Yasuda
Journal: Journal of Clinical Oncology (2022)

311 Background: The efficacy of anti-PD-1 monotherapy has been reported to be heterogeneous in each metastatic location in non-small cell lung cancer. Therefore, we analyzed the response of target lesions in each organ and the association between pattern of progression and survival in patients with gastric cancer (GC). Methods: We performed retrospective analysis, which include 148 patients with GC who received nivolumab or pembrolizumab treatment between 2017 and 2021 at eight institutions in Japan. Response rate (RR), progression free survival (PFS), and overall survival (OS) were evaluated in total patients. The percent change of target lesions of each organs was measured by CT using RECIST, and their best percent changes were compared. In the GC patients with best response of progression disease (PD), the association between pattern of progression and survival was analyzed. Systemic progression was defined as PD in two or more lesions including target or non-target lesions, and non-systemic progression was defined as PD in only one lesion. Results: Among 148 patients, the RR, median PFS, and median OS were 11.6%, 1.6 months (95%CI, 1.4-1.9), and 4.4 months (95%CI, 3.6-6.6), respectively. A total of 293 lesions from 112 patients with target lesions were examined. The median best percent change of lymph node (n = 76), liver (n = 62), peritoneum (n = 19) and lung (n = 8) was +2.3%, +27%, +12%, +8.5%, respectively. Liver had significantly the lowest responses compared with lymph node and peritoneum (p &lt; 0.0001 and p = 0.016). The median OS in non-systemic and systemic progression group was 5.6 months (95%CI, 3.6-8.8) and 3.3 months (95%CI, 1.9-3.6) and survival of patients with non-systemic progression showed significantly longer than that of systemic progression (p = 0.012). According to univariate and multivariate analysis, poor performance status (PS) (HR 1.73, 95%CI, 1.00-2.87) and systemic progression (HR 3.09, 95%CI, 1.95-4.82) were associated with OS in total patients. Additionally, liver metastasis (OR 2.99, 95%CI, 1.04-8.58) was identified as a baseline factor associated with systemic progression in the univariate and multivariate analysis. Conclusions: The efficacy of immune checkpoint inhibitor (ICI) is dependent on the metastatic location. Moreover, pattern of progression has been associated with overall survival. Liver metastasis might be a predictive factor of systemic progression in ICI treatment for GC.
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
Authors: Ghassan K. Abou-Alfa, Stephen Lam Chan, Masatoshi Kudo, George Lau, Robin Kate Kelley, Junji Furuse, Wattana Sukeepaisarnjaroen, Yoon-Koo Kang, Tu V. Dao, Enrico N. De Toni, Lorenza Rimassa, Valeriy Vladimirovich Breder, Alexander Vasilyev, Alexandra Heurgue, Vincent Tam, Kabir Mody, Satheesh Chiradoni Thungappa, Philip He, Alejandra Negro, Bruno Sangro
Journal: Journal of Clinical Oncology (2022)

379 Background: A single priming dose of T (anti-CTLA-4) added to D (anti-PD-L1) in the STRIDE (Single T Regular Interval D) regimen, formerly T300+D, showed encouraging clinical activity and limited toxicity in a phase 2 uHCC study (Study 22, NCT02519348), suggesting single exposure to T is sufficient to improve upon D activity. HIMALAYA (NCT03298451) evaluated the efficacy and safety of STRIDE or D vs sorafenib (S) in uHCC. Methods: HIMALAYA is an open-label, multicenter, phase 3 study, in which pts with uHCC and no prior systemic therapy were initially randomized to STRIDE (T 300 mg plus D 1500 mg [one dose] plus D 1500 mg every 4 weeks [Q4W]), D (1500 mg Q4W), S (400 mg twice daily), or T 75 mg Q4W (4 doses) plus D 1500 mg Q4W (T75+D). Recruitment to T75+D ceased after a planned analysis of Study 22 showed T75+D did not meaningfully differ from D. The primary objective was overall survival (OS) for STRIDE vs S. The secondary objective was OS noninferiority (NI) of D to S (NI margin: 1.08). Secondary endpoints included progression-free survival (PFS), objective response rate (ORR; RECIST v.1.1), duration of response (DoR), and safety. Results: In total, 1171 pts were randomized to STRIDE (N=393), D (N=389), or S (N=389). At data cutoff (DCO), the primary objective was met: OS was significantly improved for STRIDE vs S (hazard ratio [HR], 0.78; 96% confidence interval [CI], 0.65–0.92; p=0.0035; Table). D met the objective of OS NI to S (HR, 0.86; 96% CI, 0.73–1.03). ORRs were higher for STRIDE (20.1%) and D (17.0%) than for S (5.1%). No new safety signals were identified. Grade 3/4 treatment-related adverse events (TRAEs) occurred in 25.8% (STRIDE), 12.9% (D), and 36.9% (S) of pts. Grade 3/4 hepatic TRAEs occurred in 5.9% (STRIDE), 5.2% (D), and 4.5% (S) of pts. No TRAE of esophageal varices hemorrhage occurred. Rates of TRAEs leading to discontinuation were 8.2% (STRIDE), 4.1% (D), and 11.0% (S). Conclusions: HIMALAYA was the first large phase 3 trial with a diverse, representative uHCC population and extensive long-term follow-up to assess both mono- and combination immunotherapy. D was noninferior to S with favorable safety. The combination of a single priming dose of T plus D in STRIDE displayed superior efficacy and a favorable benefit-risk profile vs S. STRIDE is a proposed, novel, first-line standard of care systemic therapy for uHCC. Clinical trial information: NCT03298451. [Table: see text]
Bioorthogonal catalytic nanozyme-mediated lysosomal membrane leakage for targeted drug delivery
Authors: Zhiyuan Sun, Qiqi Liu, Xinyue Wang, Jin Wu, Xueyan Hu, Miaomiao Liu, Xiangyun Zhang, Yonghua Wei, Zhijun Liu, Hongjiang Liu, Rui Chen, Fei Wang, Adam C. Midgley, Aitao Li, Xiyun Yan, Yanming Wang, Jie Zhuang, Xinglu Huang
Journal: Theranostics (2022)

Rationale:Employing in situ bioorthogonal catalysis within subcellular organelles, such as lysosomes, remains a challenge.Lysosomal membranes pose an intracellular barrier for drug sequestration, thereby greatly limiting drug accumulation and concentrations at intended targets.Here, we provide a proof-of-concept report of a nanozyme-based strategy that mediates in situ bioorthogonal uncaging reactions within lysosomes, followed by lysosomal escape and the release of uncaged drugs into the cytoplasm.Methods: A model system composed of a protein-based nanozyme platform (based on the transition metals Co, Fe, Mn, Rh, Ir, Pt, Au, Ru and Pd) and caged compound fluorophores was designed to screen for nanozyme/protecting group pairings.The optimized nanozyme/protecting group pairing was then selected for utilization in the design of anti-cancer pro-drugs and drug delivery systems.Results: Our screening system identified Pd nanozymes that mimic mutant P450BM3 activity and specifically cleave propargylic ether groups.We found that the intrinsic peroxidase-like activity of Pd nanozymes induced the production of free radicals under acid conditions, resulting in lysosomal membrane leakage of uncaged molecules into the cytoplasm.Using a multienzyme synergistic approach, our Pd nanozymes achieved in situ bioorthogonal catalysis and nanozyme-mediated lysosomal membrane leakage, which were successfully applied to the design of model pro-drugs for anti-cancer therapy.The extension of our nanozyme system to the construction of a liposome-based "all-in-one" delivery system offers promise for realizing efficacious in vivo tumor-targeted therapies.Conclusions: This strategy shows a promising new direction by utilizing nanotechnology for drug development through in situ catalyzing bioorthogonal chemistry within specific subcellular organelles.
Colorectal Cancer Screening Clinical Practice Guidelines in Oncology
Authors: Bernard Levin, Kirk A Ludwig, Gideon Steinbach
Journal: Journal of the National Comprehensive Cancer Network (2003)

This article summarizes the NCCN clinical practice guidelines for screening for colorectal cancer. This guideline provides recommendations for appropriate screening and management of abnormal findings in groups at both average and high risk. In its deliberations, the Colorectal Cancer Screening Panel identified populations at high risk to include both patients with inflammatory bowel disease (ulcerative colitis and Crohn's disease) and individuals at risk because of a genetic predisposition. For the most recent version of the guidelines, please visit NCCN.org
Some legal problems of the industrial physician
Authors: W. G. Hoppe
Journal: JAMA (1977)

ONE of the industrial physician's most important responsibilities involves physical examinations of prospective or actual employees. When a physician is employed to physically examine a person in the interest of a third-party individual or corporation to determine the former's suitability for employment, a question arises regarding the relationship between the examining physician and the person to be examined. In<i>Hoover vs Williamson</i><sup>1</sup>the court said "that there is not a doctor-patient relationship between... a prospective or actual employee and the doctor who examines him for the employer." However, the court also noted that such a physician may incur liability where he "undertakes to render services which he should recognize as necessary to another's bodily safety, and leads the other in reasonable reliance on the services to refrain from taking other protective steps, or to enter on a dangerous course of conduct." If a physician fails to exercise due care
SOME PARIS CLINICS.
Authors: None H. R. B.
Journal: JAMA (1888)

(FROM OUR SPECIAL CORRSPONDENT.) Apostoli's Clinic—Verneuil's Clinic—Charcot's Clinic—Therapeutic Notes. Dr. Apostoli has a clinic for diseases of women, with special reference to the treatment of such conditions with electricity, on Monday, Thursday and Saturday, at half-past two, Rue du Jour, No. 19. I consider this to be, in many particulars, the best gynecological clinic in Europe, either: 1st. For those who wish to examine a great variety of rare as well as of ordinary cases; 2d. For those who wish to study intelligently and honestly recent methods in conservatism. Those who have raised objections to his method have done so, 1st, from theoretic reasoning; 2d, from a want of success, due probably to a want of exactness in following out necessary directions. A man is apt to believe the evidence of his own eyes, and the testimony of a multitude of reliable witnesses can be disputed only upon the ground
Extramural coronary arteries in cyanotic congenital heart disease Reema Chuch, Joseph K. Perloff, Michael C. Fishbein, Philip A. Ludbrook, Kathryn J. Junge, John S. Child. Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA, Washington University School of Medicine, St. Louis, MO
Journal: Journal of the American College of Cardiology (2001)
Re: Roman Sosnowski, Hubert Kamecki, Steven Joniau, Jochen Walz, Zachary Klaassen, Joan Palou. Introduction of Telemedicine During the COVID-19 Pandemic: A Challenge for Now, an Opportunity for the Future. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.07.007
Authors: Andrea M. Allen-Tejerina, Kathrine S. Rallis, Bernadett Szabados
Journal: European Urology (2020)
Trends in long-term survival after liver resection for gastric cancer liver metastasis: Analysis of a single-center experience over 28 years.
Authors: Hiromichi Ito, Nobuyuki Takemura, Atsushi Oba, Yoshihiro Ono, Takafumi Sato, Yosuke Inoue, Akio Saiura, Yu Takahashi
Journal: Journal of Clinical Oncology (2022)

290 Background: While systemic chemotherapy for gastric cancer has evolved significantly in the last decade, the role of surgery for liver metastasis remained controversial. The aims of this study were to examine the trend in outcomes of patients with gastric cancer liver metastasis (GCLM) undergoing resection at our center, and to define the optimal selection criteria for resection. Methods: One hundred and twenty-two consecutive patients who underwent liver resection for GCLMs with curative intent at our institution from 1993 through 2021 were included. The patients were grouped into 2 eras: era I, 1993 to 2010; era II, 2011 to 2021. Our criteria for liver resection included absence of extrahepatic disease, and the limited number of liver metastasis (often 3 or less). Median follow-up was 34 months for all and 71 months for the survivors. Results: There were 63 patients in era I and 59 in era II. The patients in era II received chemotherapy prior to liver resection more often (68% vs 41%, p = 0.004), and their primary tumor was less advanced (T3/4; 66% vs 85%, p = 0.021) with less regional lymph node metastasis (median No. of positive nodes; 4 vs 1, p = 0.034) compared to those in ear I. Median and 5-year disease-specific survival (DSS) were better in era II (not reached, 55%) than in era I (35 months, 35%, p = 0.025). In the multivariate analysis for the entire cohort, elevated CEA (&gt; 50 ng/ml), primary T4, and primary at the proximal stomach emerged as independent factors associated with shorter DSS. Number of these risk factors are highly predictive for long-term survival; among the patients without or with a single factor alone, 5-year DSS was 50%, whereas none of those with multiple risk factors survived beyond 5 years ( p&lt; 0.0001). Conclusions: Long-term outcomes for patients with oligo-GCLM has improved in the modern chemotherapy era. Liver resection should be considered unless they carry multiple risk factors.